Sign in to view content

Number of Injections and Time to Dry Analysis of Brolucizumab Versus Aflibercept in Patients With Neovascular AMD: 96-Week Data From HAWK and HARRIER

Carl D. Regillo, MD

Video
Published 2020

Related

Intravitreal Gene Therapy for Diabetic Macular Edema With ADVM-022: First-Time Data Presentation of Prospective, Randomized Phase 2 INFINITY Trial
Charles C Wykoff, MD, PhD, FASRS
Updates from the Field
2021
Baseline Factors Influencing Diabetic Macular Edema (DME) Resolution After Intravitreal Aflibercept Injection (IAI) or Laser Treatment in VISTA/VIVID
W. Lloyd Clark, MD, FASRS
Annual Meeting Talks
2021
Economic Benefit of Higher Durability Anti-VEGF Agents in the Treatment of Neovascular Macular Degeneration
Sabin Dang, MD
Annual Meeting Talks
2023

Category: AMD-Neovascular

See more